Synergistic Antitumor Activity Demonstrated in Preclinical Tumor Models

Strategic Insights -

Combining GVAX cancer vaccines with anti-angiogenesis agents that block vascular endothelial growth factor (VEGF) demonstrates significant antitumor activity in preclinical tumor models. This combination treatment shows promise in various types of cancer, including melanoma, prostate cancer, lung cancer, pancreatic cancer, leukemia, and myeloma. Preclinical studies presented at the American Association of Cancer Research (AACR) Meeting in Anaheim, California, by Cell Genesys researchers indicate a statistically significant improvement in survival in mice treated with the combination therapy compared to controls.

Key Takeaways:

  • The combination of GVAX cancer vaccine with VEGF blockade demonstrates synergistic antitumor activity in preclinical tumor models, specifically a 48% improvement in median duration of survival in mice treated with the combination compared to controls.
  • Preclinical studies show that VEGF blockade enhances the activity of dendritic cells, a type of immune cell critical to a successful vaccine response.
  • No dose-limiting toxicities were observed after treatment with the combination of VEGF blockade and GVAX cancer vaccine.
  • Clinical trials of GVAX cancer vaccines are underway for multiple types of cancer, including prostate cancer, lung cancer, pancreatic cancer, leukemia, and myeloma.
  • The preclinical data presented at the AACR Meeting demonstrate the potential benefits of combining GVAX cancer vaccines with VEGF blockade.
  • Researchers believe that this combination of immunotherapy and blockade of tumor angiogenesis represents a promising approach to the treatment of cancer.

Statistics:

  • A 48% improvement in median duration of survival was observed in mice treated with GVAX cancer vaccine combined with VEGF blockade compared to controls (p=0.009).
  • Mice treated with the combination therapy had a median survival time of 92.5 days, while controls had a median survival time of 31 days (p=0.009).
  • The preclinical studies were conducted in a melanoma mouse model, which is commonly used to evaluate experimental cancer treatments.

Sources:

  • Cell Genesys, Inc. (2005, Health & Medicine Week)
  • American Association of Cancer Research (AACR)
  • NewsRx.com